ClinicalTrials.gg
CompletedNCT01684202Updated Mar 18, 2021Results posted

A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)

A Phase 2 interventional study of OPC-41061 in Carcinomatous Edema, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-18.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Study summary

OPC-41061 will be administered to patients with volume overload associated with cancer, first by dose-escalation and subsequently for 6 consecutive days at the fixed dose at which urine volume is increased to investigate efficacy, pharmacokinetics, pharmacodynamic effects, and safety and to determine the effective initial and maintenance doses of OPC-41061.

02

Conditions studied

  • Carcinomatous Edema

Browse trials for

03

In context

Edema

568 studies on the registry are indexed under Edema; 97 are open to participants now.

This study's enrollment of 43 is below the median of 53 across 402 interventional studies indexed under Edema.

Browse Edema studies →

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects judged as having cancer by or cytology
  • Subjects with carcinomatous ascites
  • Male or female subjects between the ages of 20 and 80, inclusive (at time of )
  • Subjects with survival expectancy of at least 3 months and an (ECOG) Performance Status score (PS score) of 0 to 2
  • Subjects who are inpatients or who can be admitted to the trial site for the duration of the trial
  • Subjects who, together with their partner, are able to practice one of the specified methods until 4 weeks after final trial drug administration
  • Subjects capable of giving informed consent to participate in the trial of their own free will prior to start of the trial.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any of the following complications or symptoms:

    • Deep vein thrombosis
    • Intestinal obstruction or intestinal edema with symptoms similar to intestinal obstruction
    • Hepatic cirrhosis
    • Anuria
    • Urination impaired due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
    • Continuing symptoms of diarrhea or vomiting
    • Infection requiring systemic treatment
  • Subjects with any of the following medical histories:

    • History of cerebrovascular disorder or coronary disease within 4 weeks prior to start of the pre-observation period
    • History of or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride
    • History of gastrectomy or enterectomy to an extent affecting absorption of oral medication
  • Subjects with any of the following abnormal laboratory values:

count of \< 75,000/mm3, of \< 8.0 g/dL, of \< 1,000/mm3, total of > 4.0 g/dL, serum creatinine of > 3.0 mg/dL, serum sodium of > 147 mEq/L, or serum potassium of > 5.5 mEq/L

  • Subjects who have used albumin products (agents for treating hypoalbuminemia) or blood products containing albumins within 1 week prior to start of the pre-observation period, or after start of the pre-observation period
  • Subjects who have received any drug within 4 weeks prior to start of the pre-observation period
  • Subjects who have previously received OPC-41061
  • Subjects who have received surgical treatment or radiation therapy for cancer within 4 weeks prior to start of the pre-observation period
  • Subjects for whom the investigator or subinvestigator judges that it would be difficult to evaluate the efficacy and safety of OPC-41061 due to the effects of ongoing chemotherapy or other therapies for cancer (eg, improvement of carcinomatous ascites or development of edema due to adverse events related to therapeutic interventions other than OPC-41061)
  • Subjects who are unable to sense thirst or who have difficulty with fluid or food intake
  • Subjects who are unable to take oral medication
  • Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    OPC-41061

    Drug: OPC-41061

Interventions

  • orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.

06

What researchers measure

Primary outcomes

  1. Change in Body Weight From Baseline at Final IMP Administration

    Body weight was measured in 100-g units before breakfast and after subjects had urinated at least once, taking care to minimize fluctuations due to defecation or clothing.

    Time frame: Baseline, at the final IMP administration (shortest:7days longest:12days)

  2. Change in Ascites Volume From Baseline Measured by Computer Tomography (CT) at Final IMP Administration

    Time frame: Baseline, at the final IMP administration (shortest:7days longest:12days)

07

Results

Posted Mar 18, 2021

Participant flow

Dose-escalation Period
Participant flow — Dose-escalation Period
MilestoneOPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Started158911
Completed147911
Not completed1100
Withdrew: Adverse event0100
Withdrew: Withdrawal by subject1000
Maintenance Period
Participant flow — Maintenance Period
MilestoneOPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Started147911
Completed134810
Not completed1311
Withdrew: Adverse event1111
Withdrew: Physician decision0100
Withdrew: Withdrawal by subject0100

Outcome measures

PrimaryChange in Body Weight From Baseline at Final IMP Administration

Body weight was measured in 100-g units before breakfast and after subjects had urinated at least once, taking care to minimize fluctuations due to defecation or clothing.

Time frame:
Baseline, at the final IMP administration (shortest:7days longest:12days)
Reported as:
Mean · Kg
Change in Body Weight From Baseline at Final IMP Administration
KgOPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Change in Body Weight From Baseline at Final IMP Administration-0.69 ± 2.51-0.34 ± 1.99-1.13 ± 1.620.70 ± 1.56
PrimaryChange in Ascites Volume From Baseline Measured by Computer Tomography (CT) at Final IMP Administration
Time frame:
Baseline, at the final IMP administration (shortest:7days longest:12days)
Reported as:
Mean · mL
Change in Ascites Volume From Baseline Measured by Computer Tomography (CT) at Final IMP Administration
mLOPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Change in Ascites Volume From Baseline Measured by Computer Tomography (CT) at Final IMP Administration-77.20 ± 982.19513.97 ± 653.30153.72 ± 993.63539.93 ± 659.36

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration up to 10 days after the final IMP administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-41061 3.75 mg0/15 (0%)1/15 (6.7%)8/15 (53.3%)
OPC-41061 7.5 mg0/8 (0%)0/8 (0%)6/8 (75%)
OPC-41061 15 mg0/9 (0%)0/9 (0%)8/9 (88.9%)
OPC-41061 30 mg0/11 (0%)0/11 (0%)10/11 (90.9%)
Most frequent serious events
Most frequent serious events
EventOPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/150/80/90/11
Most frequent other events
Showing 10 of 57
Most frequent other events
EventOPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
VomitingGastrointestinal disorders2/150/82/91/11
ConstipationGastrointestinal disorders0/151/80/92/11
NauseaGastrointestinal disorders0/150/80/92/11
Renal impairmentRenal and urinary disorders0/150/81/92/11
LeukopeniaBlood and lymphatic system disorders0/151/80/90/11
NeutropeniaBlood and lymphatic system disorders0/151/81/90/11
ThrombocytopeniaBlood and lymphatic system disorders0/151/80/90/11
NasopharyngitisInfections and infestations0/151/80/90/11
Blood osmolarity increasedInvestigations1/151/80/91/11
Bile duct cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/80/90/11

Baseline characteristics

Full analysis set: all subjects who had been administered the investigational medicinal product (IMP) at least once and from whom data for efficacy endpoints were obtained after the start of IMP administration.

Age, Continuous
Age, Continuous(years)OPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mgTotal
Mean63.3 ± 9.966.1 ± 8.562.2 ± 7.669.5 ± 7.965.3 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)OPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mgTotal
Female647724
Male732416
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mgTotal
Japanese13791140
Region of Enrollment
Region of Enrollment(Participants)OPC-41061 3.75 mgOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mgTotal
Japan13791140
08

Study locations

1 site
  • Kansai Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Dec 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 7 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2012
First posted
Sep 12, 2012
Start
Jul 2012
Primary completionActual
Dec 2013
CompletionActual
Jun 2014
Results first posted
Mar 18, 2021
Last update
Mar 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01684202
Responsible party
Sponsor
First posted
Sep 12, 2012
Start date
Jul 2012
Primary completion
Dec 2013
Completion
Jun 2014
Results posted
Mar 18, 2021
Last update
Mar 18, 2021

Study contacts

Junichi Hahimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion